Search Results

Business

Clasp Therapeutics Launches With $150 Million to Pioneer Precision Immuno-Oncology Using Next-Generation T Cell Engagers With Unparalleled Specificity

Clasp Therapeutics launched today with $150 million in financing.

March 20, 2024

·

4 min read

Pictured: T cells attacking cancer/ iStock, Design

Clasp Emerges with $150M Series A Financing to Advance T Cell Engagers

Clasp Therapeutics announced Wednesday that the Series A funding, which was led in part by Novo Holdings, will support development of its T cell engagers for highly specific tumor targeting.

March 20, 2024

·

2 min read

·

Kate Goodwin

Press Releases

Clasp Therapeutics Doses First Patient in Phase 1 Clinical Trial With a First-in-Class T-Cell Engager Designed to Target Cancer Cells With Absolute Specificity

April 28, 2025

·

3 min read

Biotech Bay

CLASP IID One-year Data Confirm Safety and Efficacy of Edwards Pascal System for Degenerative Mitral Regurgitation

Edwards Lifesciences Corporation announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two contemporary mitral transcatheter edge-to-edge repair therapies, as well as one-year results from the CLASP IID registry.

October 26, 2023

·

5 min read

Drug Development

Clasp Therapeutics to Present Preclinical Data Evaluating Novel T Cell Engager Targeting p53 Mutant Solid Tumors

October 4, 2024

·

1 min read

Press Releases

Clasp Therapeutics Presents Comprehensive Preclinical Data Validating First-in-Class Precision T Cell Engager Against p53 Mutant Solid Tumors at SITC Annual Meeting

November 7, 2024

·

2 min read

Pharm Country

Atlantic Health System’s Morristown Medical Center Performs World’s First Catheter-Based Mitral Valve Repair in CLASP IID Pivotal Trial

CLASP IID Trial Will Evaluate Edwards PASCAL Transcatheter Mitral Valve Repair System

December 3, 2018

·

5 min read

Genetown

Edwards Announces Six-Month Data Confirming TEER as Safe and Effective for DMR in First Head-to-Head Trial

Edwards Lifesciences Corporation announced results from CLASP IID, the first randomized controlled trial that directly compares two contemporary transcatheter edge-to-edge repair therapies.

September 17, 2022

·

6 min read

Press Releases

Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibrosis Portfolio

January 7, 2026

·

5 min read

Clasp Therapeutics